Genmab — Marts 2026
-
Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial / Amlenetug https://news.cision.com/h--lundbeck-a-s/r/lundbeck-announces-last-patient-randomized-ahead-of-schedule-in-phase-3-mascot-trial,c4318514
-
3 Acasunlimab posters at the European Lung Cancer Congress in Copenhagen later in March. Oh well, it is what it is.
https://cslide.ctimeetingtech.com/coasis_21526/attendee/confcal_1/presentation/list?q=acasunlimab -
TECVAYLI
▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy https://uk.finance.yahoo.com/news/tecvayli-teclistamab-monotherapy-application-submitted-092900331.html -
As long as Genmab can have a strategic partnership with this new "sister-company" as well, is what I am more interested in. As these two individuals clearly have the abillity and focus to innovate new "knock-your-socks-off" products!
-
Argh.... Måske ikke lige det dobbelte, men enig i at kursen burde ligge et helt andet leje..... Det skræmmende er at hovedparten af analysehusene har haft target kurser et godt stykke over 2000 igennem et par år, og de bliver ufortrødent ved. - Hvilket faktisk er ret usædvanligt for en faldende aktie - der plejer de faktisk at følge med ned...... Hvorom alting er, så siger markedet noget andet..
-
For at nå mit RSI-target på 27–30 på dagskortet kræver det sandsynligvis et yderligere fald på 5–10 % (til ca. 1.550–1.620 DKK) over de kommende uger, med vedvarende nedadgående momentum. Det er ikke hugget i sten, at vi skal under RSI 30, men historisk set sker ekstremt oversolgte dips (RSI ≤ 30) ca. hver 6–8 måneder i gennemsnit (ca. 206 dage mellem events de sidste 13 år). Sidste gang var i april 2025.
-
Robotterne (folkene bag) venter lige på generalforsamlingen, og så vil det vise sig om det bliver en sommer med aktietørke for Genmab eller et sommerrally.
-
Hvis ikke I allerede har gjort det, så indgiv jeres stemmer til generalforsamlingen online på forhånd via Genmabs investorportal, hvis ikke I møder op eller har en repræsentant for at kunne stemme på selve generalforsamlingen i morgen kl. 14. Alle stemmer tæller, hvis I er enige/uenige med beslutningerne.
-
1761 / 6 - Tissue Factor expression is associated with B7-H4-mediated immune evasion in ovarian clear cell carcinoma and with response to tisotumab vedotin in preclinical models https://www.abstractsonline.com/pp8/#!/21436/presentation/4318
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind